JSJaichandran Sivalingam

Jaichandran Sivalingam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaichandran Sivalingam has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Wai Har Ng

    Division of Medical Sciences, Laboratory of Applied Human Genetics, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore, Republic of Singapore

    5 shared publications
  • Oi Lian Kon

    Division of Medical Sciences, National Cancer Centre Singapore, Republic of Singapore

    4 shared publications
  • Shaul Reuveny

    Stem Cell Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore 138668, Republic of Singapore

    4 shared publications
  • Sze Sing Lee

    Division of Medical Sciences, Laboratory of Applied Human Genetics, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore, Republic of Singapore

    4 shared publications
  • Yuin-Han Loh

    Epigenetics and Cell Fates Laboratory, Cell Fate Engineering and Therapeutics Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive Proteos, Singapore 138673, Singapore

    4 shared publications
  • Alan Tin-Lun Lam

    Bioprocessing Technology Institute, 20 Biopolis Way, Centros #06-01, Singapore, 138668, Singapore

    3 shared publications

Latest Publications

  • Review: In vitro generation of red blood cells for transfusion medicine: Progress, prospects and challenges

    by Esmond Lee, Jaichandran Sivalingam, Zhong Ri Lim, Gloryn Chia, Low Gin Shi, Mackenna Roberts, Yuin-Han Loh, Shaul Reuveny, Steve Kah-Weng Oh


  • Integrated Multimodal Evaluation of Genotoxicity in ZFN-Modified Primary Human Cells

    by Jaichandran Sivalingam, Dimitar Kenanov, Wai Har Ng, Sze Sing Lee, Toan Thang Phan, Sebastian Maurer-Stroh, Oi Lian Kon

    Iatrogenic adverse events in clinical trials of retroviral vector-mediated gene-corrected cells have prioritized the urgent need for more comprehensive and stringent assessment of potentially genotoxic off-target alterations and the biosafety of cells intended for therapeutic applications. Genome editing tools such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced palindromic repeats (CRISPR)-Cas9 nuclease systems are being investigated as safer and efficient alternatives for site-directed genome modification. Using site-specific integration into the AAVS1 locus of primary human cells as an example, we present an integrated approach to multimodal investigation of off-target alterations and an evaluation of potential genotoxicity induced by ZFN-mediated integration of a therapeutic transgene.

  • Open Access

    Durable engraftment of genetically modified FVIII‐secreting autologous bone marrow stromal cells in the intramedullary microenvironment

    by Sze Sing Lee, Jaichandran Sivalingam, Ajit J. Nirmal, Wai Har Ng, Irene Kee, In Chin Song, Chin Yong Kiong, Kristoffer A. Gales, Frederic Chua, Edgar M. Pena, et al.

    Genetically modified FVIII‐expressing autologous bone marrow‐derived mesenchymal stromal cells (BMSCs) could cure haemophilia A. However, culture‐expanded BMSCs engraft poorly in extramedullary sites. Here, we compared the intramedullary cavity, skeletal muscle, subcutaneous tissue and systemic circulation as tissue microenvironments that could support durable engraftment of FVIII‐secreting BMSC in vivo. A zinc finger nuclease integrated human FVIII transgene into PPP1R12C (intron 1) of culture‐expanded primary canine BMSCs. FVIII‐secretory capacity of implanted BMSCs in each dog was expressed as an individualized therapy index (number of viable BMSCs implanted × FVIII activity secreted/million BMSCs/24 hours). Plasma samples before and after implantation were assayed for transgenic FVIII protein using an anti‐human FVIII antibody having negligible cross‐reactivity with canine FVIII. Plasma transgenic FVIII persisted for at least 48 weeks after implantation in the intramedullary cavity. Transgenic FVIII protein levels were low after intramuscular implantation and undetectable after both intravenous infusion and subcutaneous implantation. All plasma samples were negative for anti‐human FVIII antibodies. Plasma concentrations and durability of transgenic FVIII secretion showed no correlation with the therapy index. Thus, the implantation site microenvironment is crucial. The intramedullary microenvironment, but not extramedullary tissues, supported durable engraftment of genetically modified autologous FVIII‐secreting BMSCs.


  • Improved erythroid differentiation of multiple human pluripotent stem cell lines in microcarrier culture by modulation of Wnt/β-Catenin signaling

    by Jaichandran Sivalingam, Hong Yu Chen, Bin-Xia Yang, Zhong Ri Lim, Alan Tin Lun Lam, Tsung Liang Woo, Allen Kuan-Liang Chen, Shaul Reuveny, Yuin-Han Loh, Steve Kah-Weng Oh


  • Defined Serum‐Free Medium for Bioreactor Culture of an Immortalized Human Erythroblast Cell Line

    by Esmond Lee, Zhong Ri Lim, Hong‐Yu Chen, Bin Xia Yang, Alan Tin‐Lun Lam, Allen Kuan‐Liang Chen, Jaichandran Sivalingam, Shaul Reuveny, Yuin‐Han Loh, Steve Kah‐Weng Oh

    Anticipated shortages in donated blood supply have prompted investigation of alternative approaches for in vitro production of red blood cells (RBCs), such as expansion of conditional immortalization erythroid progenitors. However, there is a bioprocessing challenge wherein factors promoting maximal cell expansion and growth‐limiting inhibitory factors are yet to be investigated. The authors use an erythroblast cell line (ImEry) derived from immortalizing CD71+CD235a+ erythroblast from adult peripheral blood for optimization of expansion culture conditions. Design of experiments (DOE) is used in media formulation to explore relationships and interactive effects between factors which affect cell expansion. Our in‐house optimized medium formulation produced significantly higher cell densities (3.62 ± 0.055) × 106 cells mL−1, n = 3) compared to commercial formulations (2.07 ± 0.055) × 106 cells mL−1, n = 3; at 209 h culture). Culture media costs per unit of blood is shown to have a 2.96–3.09 times cost reduction. As a proof of principle for scale up, ImEry are expanded in a half‐liter stirred‐bioreactor under controlled settings. Growth characteristics, metabolic, and molecular profile of the cells are evaluated. ImEry has identical O2 binding capacity to adult erythroblasts. Amino acid supplementation results in further yield improvements. The study serves as a first step for scaling up erythroblast expansion in controlled bioreactors.


  • Superior Red Blood Cell Generation from Human Pluripotent Stem Cells Through a Novel Microcarrier-Based Embryoid Body Platform

    by Jaichandran Sivalingam, Alan Tin-Lun Lam, Hong Yu Chen, Bin Xia Yang, Allen Kuan-Liang Chen, Shaul Reuveny, Yuin-Han Loh, Steve Kah-Weng Oh

    In vitro generation of red blood cells (RBCs) from human embryonic stem cells and human induced pluripotent stem cells appears to be a promising alternate approach to circumvent shortages in donor-derived blood supplies for clinical applications. Conventional methods for hematopoietic differentiation of human pluripotent stem cells (hPSC) rely on embryoid body (EB) formation and/or coculture with xenogeneic cell lines. However, most current methods for hPSC expansion and EB formation are not amenable for scale-up to levels required for large-scale RBC generation. Moreover, differentiation methods that rely on xenogenic cell lines would face obstacles for future clinical translation. In this study, we report the development of a serum-free and chemically defined microcarrier-based suspension culture platform for scalable hPSC expansion and EB formation. Improved survival and better quality EBs generated with the microcarrier-based method resulted in significantly improved mesoderm induction and, when combined with hematopoietic differentiation, resulted in at least a 6-fold improvement in hematopoietic precursor expansion, potentially culminating in a 80-fold improvement in the yield of RBC generation compared to a conventional EB-based differentiation method. In addition, we report efficient terminal maturation and generation of mature enucleated RBCs using a coculture system that comprised primary human mesenchymal stromal cells. The microcarrier-based platform could prove to be an appealing strategy for future scale-up of hPSC culture, EB generation, and large-scale generation of RBCs under defined and xeno-free conditions.


  • Open Access

    Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells

    by Jaichandran Sivalingam, Dimitar Kenanov, Hao Han, Ajit Johnson Nirmal, Wai Har Ng, Sze Sing Lee, Jeyakumar Masilamani, Toan Thang Phan, Sebastian Maurer-Stroh, Oi Lian Kon


  • Open Access

    Biosafety Assessment of Site-directed Transgene Integration in Human Umbilical Cord–lining Cells

    by Jaichandran Sivalingam, Shruti Krishnan, Wai Har Ng, Sze Sing Lee, Toan Thang Phan, Oi Lian Kon


  • Open Access

    Nonvirally Modified Autologous Primary Hepatocytes Correct Diabetes and Prevent Target Organ Injury in a Large Preclinical Model

    by Nelson K. F. Chen, Jen San Wong, Irene H. C. Kee, Siang Hui Lai, Choon Hua Thng, Wai Har Ng, Robert T. H. Ng, Soo Yong Tan, Shu Yen Lee, Mark E. H. Tan, et al.

    Current gene- and cell-based therapies have significant limitations which impede widespread clinical application. Taking diabetes mellitus as a paradigm, we have sought to overcome these limitations by ex vivo electrotransfer of a nonviral insulin expression vector into primary hepatocytes followed by immediate autologous reimplantation in a preclinical model of diabetes. In a single 3-hour procedure, hepatocytes were isolated from a surgically resected liver wedge, electroporated with an insulin expression plasmid ex vivo and reimplanted intraparenchymally under ultrasonic guidance into the liver in each of 10 streptozotocin-induced diabetic Yorkshire pigs. The vector was comprised of a bifunctional, glucose-responsive promoter linked to human insulin cDNA. Ambient glucose concentrations appropriately altered human insulin mRNA expression and C-peptide secretion within minutes in vitro and in vivo. Treated swine showed correction of hyperglycemia, glucose intolerance, dyslipidemia and other metabolic abnormalities for ≥47 weeks. Metabolic correction correlated significantly with the number of hepatocytes implanted. Importantly, we observed no hypoglycemia even under fasting conditions. Direct intrahepatic implantation of hepatocytes did not alter biochemical indices of liver function or induce abnormal hepatic lobular architecture. About 70% of implanted hepatocytes functionally engrafted, appeared histologically normal, retained vector DNA and expressed human insulin for ≥47 weeks. Based on structural tissue analyses and transcriptome data, we showed that early correction of diabetes attenuated and even prevented pathological changes in the eye, kidney, liver and aorta. We demonstrate that autologous hepatocytes can be efficiently, simply and safely modified by electroporation of a nonviral vector to express, process and secrete insulin durably. This strategy, which achieved significant and sustained therapeutic efficacy in a large preclinical model without adverse effects, warrants consideration for clinical development especially as it could have broader future applications for the treatment of other acquired and inherited diseases for which systemic reconstitution of a specific protein deficiency is critical.